<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3788">
  <stage>Registered</stage>
  <submitdate>16/01/2013</submitdate>
  <approvaldate>16/01/2013</approvaldate>
  <nctid>NCT01780506</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-004458-27</secondaryid>
    <secondaryid>GS-US-292-0104</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - E/C/F/TAF
Treatment: drugs - E/C/F/TDF
Treatment: drugs - E/C/F/TDF Placebo
Treatment: drugs - E/C/F/TAF Placebo

Experimental: E/C/F/TAF - E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks

Active Comparator: E/C/F/TDF - E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks


Treatment: drugs: E/C/F/TAF
E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily

Treatment: drugs: E/C/F/TDF
E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily

Treatment: drugs: E/C/F/TDF Placebo
E/C/F/TDF placebo tablet administered orally once daily

Treatment: drugs: E/C/F/TAF Placebo
E/C/F/TAF placebo tablet administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 - The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96 - The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Weeks 48 and 96 - The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</outcome>
      <timepoint>Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in CD4+ Cell Count at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in CD4+ Cell Count at Week 96</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 - Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Hip BMD at Week 96 - Hip BMD was assessed by DXA scan.</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Spine BMD at Week 48 - Spine BMD was assessed by DXA scan.</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Spine BMD at Week 96 - Spine BMD was assessed by DXA scan.</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Creatinine at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Creatinine at Week 96</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48 - Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96 - Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.</outcome>
      <timepoint>Up to 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 - Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 - Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48 - Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96 - Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.</outcome>
      <timepoint>Baseline; Week 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Ability to understand and sign a written informed consent form, which must be obtained
             prior to initiation of study procedures

          -  Plasma HIV-1 RNA levels = 1,000 copies/mL at screening

          -  No prior use of any approved or investigational antiretroviral drug for any length of
             time, except the use for pre-exposure prophylaxis (PREP) or post-exposure prophylaxis
             (PEP), up to 6 months prior to screening

          -  Screening genotype report must show sensitivity to elvitegravir, emtricitabine,
             tenofovir disoproxil fumarate (tenofovir DF)

          -  Normal electrocardiogram (ECG)

          -  Estimated glomerular filtration rate (eGFR) = 50 mL/min according to the
             Cockcroft-Gault formula for creatinine clearance

          -  Hepatic transaminases (AST and ALT) = 5 × upper limit of normal (ULN)

          -  Total bilirubin = 1.5 mg/dL, or normal direct bilirubin

          -  Adequate hematologic function

          -  Serum amylase = 5 × ULN

          -  Males and females of childbearing potential must agree to utilize highly effective
             contraception methods or be non-heterosexually active or practice sexual abstinence
             from screening throughout the duration of study treatment and for 30 days following
             the last dose of study drug

          -  Females who utilize hormonal contraceptive as one of their birth control methods must
             have used the same method for at least three months prior to study dosing

          -  Females who have stopped menstruating for = 12 months but do not have documentation of
             ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at
             screening within the post-menopausal range based on the Central Laboratory reference
             range

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A new acquired immunodeficiency syndrome (AIDS) defining condition diagnosed within
             the 30 days prior to screening

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Hepatitis C antibody positive

          -  Individuals experiencing decompensated cirrhosis

          -  Females who are breastfeeding

          -  Positive serum pregnancy test

          -  Have an implanted defibrillator or pacemaker

          -  Current alcohol or substance use judged by the Investigator to potentially interfere
             with study compliance

          -  History of malignancy within the past 5 years or ongoing malignancy other than
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
             squamous carcinoma

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to baseline

          -  Any other clinical condition or prior therapy that, in the opinion of the
             Investigator, would make the individual unsuitable for the study or unable to comply
             with dosing requirements

          -  Participation in any other clinical trial (including observational trials) without
             prior approval

          -  Individuals receiving ongoing therapy with drugs not to be used with elvitegravir,
             cobicistat, emtricitabine, tenofovir DF, and TAF or individuals with any known
             allergies to the excipients of E/C/F/TDF or E/C/F/TAF single-tablet regimen tablets

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>26/12/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>872</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Holdsworth House Medical Practice - Darlinghurst</hospital>
    <hospital>Taylor Square Private Clinic - Darlington</hospital>
    <hospital>East Sydney Doctors - Sydney</hospital>
    <hospital>Albion Street Centre - Sydney</hospital>
    <hospital>Melbourne Sexual Health Clinic - Carlton</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2010 - Darlington</postcode>
    <postcode>2010 NSW - Sydney</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode>3053 - Carlton</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinjuku-ku, Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Berne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Nontaburi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir
      alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus
      elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF)
      FDC in HIV-1 positive, antiretroviral treatment-naive adults.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01780506</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>